Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

An archived webcast will be available following the event.
Taiwan News

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer ...

Abstract from trial evaluating Alpha DaRT ® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium ...
Nasdaq

Alpha Tau Medical Achieves MDSAP Certification for Jerusalem Manufacturing Facility

Alpha Tau Medical Ltd. announced that it has achieved Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem, which is a key step in ensuring quality, ...
Nasdaq

Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at ...

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Yahoo Finance

Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters

JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...